Vargyas J M, Campeau J D, Mishell D R
Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles.
Am J Obstet Gynecol. 1987 Oct;157(4 Pt 1):944-50. doi: 10.1016/s0002-9378(87)80093-5.
A double-blind, placebo-controlled crossover trial was undertaken to determine the efficacy of meclofenamate sodium in the treatment of menorrhagia. Twenty-nine patients who had a baseline menstrual blood loss greater than 60 ml received 2 months' each of meclofenamate sodium, 100 mg by mouth, three times a day, or a placebo. The mean menstrual blood loss was reduced from 141.6 +/- 15.9 ml at baseline to 69.0 +/- 6.3 ml during treatment cycles but remained increased during placebo cycles (135.6 +/- 11.3 ml). The symptoms of dysmenorrhea, backache, and headache were significantly reduced only during active drug periods. The number of days of flow and pads or tampons used was also reduced during drug cycles but not during placebo cycles. Overall, 26 of the 29 patients evaluated had a reduction in menstrual blood loss with the use of meclofenamate sodium. It appears that many women with unexplained menorrhagia may benefit from this treatment.
进行了一项双盲、安慰剂对照的交叉试验，以确定甲氯芬那酸钠治疗月经过多的疗效。29例基线月经失血量大于60ml的患者，分别接受为期2个月的甲氯芬那酸钠治疗，口服100mg，每日3次，或接受安慰剂治疗。治疗周期中，平均月经失血量从基线时的141.6±15.9ml降至69.0±6.3ml，但在安慰剂周期中仍增加（135.6±11.3ml）。仅在使用活性药物期间，痛经、背痛和头痛症状显著减轻。月经天数以及使用卫生巾或卫生棉条的数量在药物周期中也减少，但在安慰剂周期中未减少。总体而言，29例接受评估的患者中有26例使用甲氯芬那酸钠后月经失血量减少。看来许多不明原因月经过多的女性可能会从这种治疗中获益。
